Effects of beta-agonists on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease
| Autor: | Vanni Galavotti, Spyridion Papiris, C. Sturani |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Pulmonary and Respiratory Medicine
Physical Exertion Vital Capacity Pulmonary disease Maximal Midexpiratory Flow Rate Placebos Forced Expiratory Volume medicine Humans In patient Albuterol Clenbuterol Lung Diseases Obstructive Beta (finance) Aged COPD Clinical Trials as Topic business.industry Middle Aged medicine.disease respiratory tract diseases Dyspnea Ethanolamines Anesthesia Salbutamol Volatilization business medicine.drug |
| Zdroj: | Respiration; international review of thoracic diseases. 49(2) |
| ISSN: | 0025-7931 |
| Popis: | In a single-blind placebo-controlled trial in 12 patients with advanced chronic obstructive pulmonary disease (COPD) we compared the effects of nebulized salbutamol (1 mg), clenbuterol (30 micrograms) and placebo (4 ml of normal saline) on spirometric indices (FVC, FEV1), maximal expiratory flows (Vmax50 and Vmax25), the distance walked in 6 min (6MD), assessment of breathlessness by visual analogue scale (VAS), and estimates by the patients of perceived exertion (RPE). Both clenbuterol and salbutamol produced significant increases in FEV1, FVC, Vmax50 and Vmax25. With both drugs, 6MD increased significantly (p less than 0.01) and breathlessness decreased significantly without an appreciable increase in RPE after exercise despite the extra distance covered. The absolute improvements in FEV1 and 6MD after clenbuterol were correlated (r = 0.763, p less than 0.01), but these indices were not correlated after salbutamol (r = 0.121, p greater than 0.1). The lack of correlation between the changes in 6MD and FEV1 after salbutamol might indicate that relief of airways obstruction is not the only explanation for the effects on distance walked, at least with salbutamol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|